Disabling c-Myc in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent G-quadruplex interactive agent S2T1-6OTD

Molecular Cancer Therapeutics

Volumn 9, Issue 1, 2010, Pages 167-179

  Shalaby, Tarek ^a   Von Bueren, André O ^a   Hürlimann, Marie Louise ^a   Fiaschetti, Giulio ^a   Castelletti, Deborah ^a   Masayuki, Tera ^c   Nagasawa, Kazuo ^c   Arcaro, Alexandre ^a   Jelesarov, Ilian ^b   Shin ya, Kazuo ^d   Grotzer, Michael ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^d NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; GUANINE QUADRUPLEX; MESSENGER RNA; MYC PROTEIN; PROTEIN INHIBITOR; S2T1 6OTD; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TELOMESTATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN CANCER; BRAIN TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CHILDHOOD CANCER; CIRCULAR DICHROISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SEQUENCE; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG STRUCTURE; ENZYME ACTIVITY; GENE ACTIVITY; HUMAN; HUMAN TISSUE; LONG TERM CARE; MEDULLOBLASTOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOID TUMOR; SEQUENCE ANALYSIS; SHORT COURSE THERAPY; TELOMERE; TERATOMA; TRANSCRIPTION REGULATION; TREATMENT DURATION; WESTERN BLOTTING;

APOPTOSIS; BASE SEQUENCE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; G-QUADRUPLEXES; HUMANS; MEDULLOBLASTOMA; OXAZOLES; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC; RHABDOID TUMOR; RNA, MESSENGER; TELOMERASE; TERATOMA; TIME FACTORS;

EID: 73949089251     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0586     Document Type: Article

References (82)

1. Rood BR, Macdonald TJ, Packer RJ. Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol 2004;31:666-75.
2. Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg 1996;85:56-65.
3. MacDonald TJ, Rood BR, Santi MR, et al. Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors. Oncologist 2003;8:174-86.
4. Judkins AR, Mauger J, Ht A, et al. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol 2004;28:644-50.
5. Biegel JA, Tan L, Zhang F, et al. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res 2002;8:3461-7.
6. Burger PC, Yu IT, Tihan T, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol 1998;22:1083-92.
7. Bambakidis NC, Robinson S, Cohen M, et al. Atypical teratoid/rhabdoid tumors of the central nervous system: clinical, radiographic and pathologic features. Pediatr Neurosurg 2002;37:64-70.
8. Hilden JM, Meerbaum S, Burger P, et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 2004;22:2877-84.
9. Tekautz TM, Fuller CE, Blaney S, et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 2005;23:1491-9.
10. Shin-ya K, Wierzba K, Matsuo K, et al. Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J Am Chem Soc 2001;123:1262-3.
11. Tahara H, Shin-Ya K, Seimiya H, et al. G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3′ telomeric overhang in cancer cells. Oncogene 2006;25:1955-66.
12. Shammas MA, Reis RJ, Li C, et al. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res 2004;10:770-6.
13. Tauchi T, Shin-Ya K, Sashida G, et al. Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene 2003;22:5338-47.
14. Binz N, Shalaby T, Rivera P, et al. Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells. Eur J Cancer 2005;41:2873-81.
15. Tera M, Iida K, Ishizuka H, et al. Synthesis of a potent G-quadruplex-binding macrocyclic heptaoxazole. Chembiochem 2009;10:431-5.
16. Kim MY, Vankayalapati H, Shin-Ya K, et al. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. JAmChemSoc 2002;124:2098-9.
17. Siddiqui-Jain A, Grand CL, Bearss DJ, et al. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci U S A 2002;99:11593-8.
18. Siebenlist U, Hennighausen L, Battey J, et al. Chromatin structure and protein binding in the putative regulatory region of the c-myc gene in Burkitt lymphoma. Cell 1984;37:381-91.
19. Cooney M, Czernuszewicz G, Postel EH, et al. Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science 1988;241:456-9.
20. Davis TL, Firulli AB, Kinniburgh AJ. Ribonucleoprotein and protein factors bind to an H-DNA-forming c-myc DNA element: possible regulators of the c-myc gene. Proc Natl Acad Sci U S A 1989;86:9682-6.
21. Berberich SJ, Postel EH. PuF/NM23-H2/NDPK-B transactivates a human c-myc promoter-CAT gene via a functional nuclease hypersensitive element. Oncogene 1995;10:2343-7.
22. Grand CL, Han H, Munoz RM, et al. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther 2002;1:565-73.
23. Hurley LH, Von Hoff DD, Siddiqui-Jain A, et al. Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element. Semin Oncol 2006;33:498-512.
24. Obaya AJ, Mateyak MK, Sedivy JM. Mysterious liaisons: the relationship between c-Myc and the cell cycle. Oncogene 1999;18:2934-41.
25. Schmidt EV. The role of c-myc in cellular growth control. Oncogene 1999;18:2988-96.
26. Trumpp A, Refaeli Y, Oskarsson T, et al. c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 2001;414:768-73.
27. Wang J, Xie LY, Allan S, et al. Myc activates telomerase. Genes Dev 1998;12:1769-74.
28. Wu KJ, Grandori C, Amacker M, et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999;21:220-4.
29. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999;4:199-207.
30. Shachaf CM, Kopelman AM, Arvanitis C, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112-7.
31. D'Cruz CM, Gunther EJ, Boxer RB, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001;7:235-9.
32. Arnold I, Watt FM. c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr Biol 2001;11:558-68.
33. Grotzer MA, Castelletti D, Fiaschetti G, et al. Targeting Myc in pediatric malignancies of the central and peripheral nervous system. Curr Cancer Drug Targets 2009;9:176-88.
34. Scheurlen WG, Schwabe GC, Joos S, et al. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 1998;16:2478-85.
35. Badiali M, Pession A, Basso G, et al. N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification. Tumori 1991;77:118-21.
36. Herms J, Neidt I, Lüscher B, et al. C-myc expression in medulloblastoma and its prognostic value. Int J Cancer 2000;89:395-402.
37. Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001;7:2425-33.
38. Bruggers CS, Tai KF, Murdock T, et al. Expression of the c-Myc protein in childhood medulloblastoma. J Pediatr Hematol Oncol 1998;20:18-25.
39. Bigner SH, Friedman HS, Vogelstein B, et al. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res 1990;50:2347-50.
40. Aldosari N, Bigner SH, Burger PC, et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 2002;126:540-5.
41. Giangaspero F, Rigobello L, Badiali M, et al. Large-cell medulloblastomas: a distinct variant with highly aggressive behavior. Am J Surg Pathol 1992;16:687-93.
42. Eberhart CG, Kratz JE, Schuster A, et al. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 2002;12:36-44.
43. Jay V, Squire J, Bayani J, et al. Oncogene amplification in medulloblastoma: analysis of a case by comparative genomic hybridization and fluorescence in situ hybridization. Pathology 1999;31:337-44.
44. Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004;63:441-9.
45. Stearns D, Chaudhry A, Abel TW, et al. c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res 2006;66:673-81.
46. Tera M, Ishizuka H, Takagi M, et al. Macrocyclic hexaoxazoles as sequence- and mode-selective G-quadruplex binders. Angew Chem Int Ed Engl 2008;47:5557-60.
47. Didiano D, Shalaby T, Lang D, et al. Telomere maintenance in childhood primitive neuroectodermal brain tumors. Neuro-oncol 2004;6:1-8.
48. Kunz F, Shalaby T, Lang D, et al. Quantitative mRNA expression analysis of neurotrophin-receptor TrkC and oncogene c-MYC from formalin-fixed, paraffin-embedded primitive neuroectodermal tumor samples. Neuropathology 2006;26:393-9.
49. von Bueren AO, Shalaby T, Rajtarova J, et al. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells. BMC Cancer 2007;7:19.
50. Sharma-Walia N, Krishnan HH, Naranatt PP, et al. ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection. J Virol 2005;79:10308-29.
51. Riou JF, Guittat L, Mailliet P, et al. Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc Natl Acad Sci U S A 2002;99:2672-7.
52. Grotzer MA, Janss AJ, Fung K, et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 2000;18:1027-35.
53. Grotzer MA, Janss AJ, Phillips PC, et al. Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors. Klin Padiatr 2000;212:196-9.
54. Lemarteleur T, Gomez D, Paterski R, et al. Stabilization of the c-myc gene promoter quadruplex by specific ligands' inhibitors of telomerase. Biochem Biophys Res Commun 2004;323:802-8.
55. Freyer MW, Buscaglia R, Kaplan K, et al. Biophysical studies of the c-MYC NHE III1 promoter: model quadruplex interactions with a cationic porphyrin. Biophys J 2007;92:2007-15.
56. Seenisamy J, Rezler EM, Powell TJ, et al. The dynamic character of the G-quadruplex element in the c-MYC promoter and modification by TMPyP4. J Am Chem Soc 2004;126:8702-9.
57. Sanchez-Ruiz JM. Ligand effects on protein thermodynamic stability. Biophys Chem 2007;126:43-9.
58. Reed J, Gunaratnam M, Beltran M, et al. TRAP-LIG, a modified telomere repeat amplification protocol assay to quantitate telomerase inhibition by small molecules. Anal Biochem 2008;380:99-105.
59. Facchini LM, Penn LZ. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J 1998;12:633-51.
60. Simonsson T, Henriksson M. c-myc suppression in Burkitt's lymphoma cells. Biochem Biophys Res Commun 2002;290:11-5.
61. Mateyak MK, Obaya AJ, Adachi S, et al. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 1997;8:1039-48.
62. Hopewell R, Ziff EB. The nerve growth factor-responsive PC12 cell line does not express the Myc dimerization partner Max. Mol Cell Biol 1995;15:3470-8.
63. Jacobs JP, Jones CM, Baille JP. Characteristics of a human diploid cell designated MRC-5. Nature 1970;227:168-70.
64. Zhu H, Gooderham N. Neoplastic transformation of human lung fibroblast MRC-5 SV2 cells induced by benzo[a]pyrene and confluence culture. Cancer Res 2002;62:4605-9.
65. Bodnar AG, Ouelette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349-52.
66. Dexheimer TS, Carey SS, Zuohe S, et al. NM23-H2 may play an indirect role in transcriptional activation of c-myc gene expression but does not cleave the nuclease hypersensitive element III1. Mol Cancer Ther 2009;8:1363-77.
67. Huppert JL, Balasubramanian S. G-quadruplexes in promoters throughout the human genome. Nucleic Acids Res 2007;35:406-13.
68. Gonzalez V, Guo K, Hurley L, Sun D. Identification and characterization of nucleolin as a c-myc G-quadruplex-binding protein. J Biol Chem 2009;284:23622-35.
69. Rovera G, Olashaw N, Meo P. Terminal differentiation in human promyelocytic leukaemic cells in the absence of DNA synthesis. Nature 1980;284:69-70.
70. Westin EH, Wong-Staal F, Gelmann EP, et al. Expression of cellular homologues of retroviral onc genes in human hematopoietic cells. Proc Natl Acad Sci U S A 1982;79:2490-4.
71. Grosso LE, Pitot HC. Modulation of c-myc expression in the HL-60 cell line. Biochem Biophys Res Commun 1984;119:473-80.
72. Reitsma PH, Rothberg PG, Astrin SM, et al. Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite. Nature 1983;306:492-4.
73. Marampon F, Ciccarelli C, Zani BM. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol Cancer 2006;5:31.
74. Kim YH, Buchholz MA, Chrest FJ, et al. Up-regulation of c-myc induces the gene expression of the murine homologues of p34cdc2 and cyclin-dependent kinase-2 in T lymphocytes. J Immunol 1994;152:4328-35.
75. Abaza MS, Al-Saffar A, Al-Sawan S, et al. c-myc antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs. Tumour Biol 2008;29:287-303.
76. 1 arrest. Nature 1985;313:597-600.
77. Waters CM, Littlewood TD, Hancock DC, et al. c-myc protein expression in untransformed fibroblasts. Oncogene 1991;6:797-805.
78. Hahn WC, Meyerson M. Telomerase activation, cellular immortalization and cancer. Ann Med 2001;33:123-9.
79. Oh S, Song YH, Kim UJ, et al. In vivo and in vitro analyses of Myc for differential promoter activities of the human telomerase (hTERT) gene in normal and tumor cells. Biochem Biophys Res Commun 1999;263:361-5.
80. Hao H, Nancai Y, Lei F, et al. siRNA directed against c-Myc inhibits proliferation and downregulates human telomerase reverse transcriptase in human colon cancer Colo 320 cells. J Exp Clin Cancer Res 2008;27:27.
81. Greenberg RA, O'Hagan RC, Deng H, et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 1999;18:1219-26.
82. Kyo S, Takakura M, Taira T, et al. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 2000;28:669-77.